1. Relatore della sessione “Point and Counterpoint session” intitolata“PDE5 inhibitors in Patients with PrematureEjaculation but not ED?” durante il 9° Meeting della European Society for Sexual Medicine (3-6 Dicembre, 2006, Vienna, Austria).
  2. Relatore durante il 9o Congresso dell’European Federation of Sexuology: “Current Perspectives in Sexual Dysfunction: New Choices for the Couple” (Satellite Symposium Pfizer; 13-17 Aprile,2008, Roma, Italia).
  3. Relatore durante il 23o Meeting dell’European Association of Urology “PDE5 inhibitors, erectile dysfunction and prostate disease”: “Erectile dysfunction, vascular disease and PDE5 inhibitors”, (Satellite Symposium Lilly; 26-29 Marzo, 2008, Milano, Italia).
  4. Relatore durante l’European School of Oncology (ESO) Inside Track Conference “Predictive modeling in prostate cancer”: “Predictive models in andrology” (17-19 Aprile, 2008, Venezia, Italia).
  5. Relatore durante la 4o edizione dell’Experts on Sexual Medicine Meeting (REMS): “Prostate Cancer and Erectile dysfunction”: “Penile rehabilitation: clinical evidence and performance protocol” (18 Dicembre, 2008, Madrid, Spagna).
  6. Relatore durante lìEuropean Regional Medical Conference “The ED puzzle: filling the gaps with the right pieces”: “Penile Rehabilitation: Improving Patient Outcome In Silence” (3-4 Ottobre, 2008, Copenhagen, Deanimarca).
  7. Relatore durante l’Autumn Meeting of the Genito-Urinary group of the European Organization for Research and Treatment of Cancer: “Novel aspects in the treatment of prostate cancer” (9-11 Ottobre, 2008, Palermo, Italia).
  8. Relatore durante il 24o Meeting dell’European Association of Urology “BPH/LUTS: Role of inflammation and clinical consequences”: “Why does BPH develop?”, (Satellite Symposium Pierre Fabre; 17- 21 Marzo, 2009, Stoccolma, Svezia).
  9. Relatore durante l’Autumn Meeting of the Genito-Urinary group of the European Organization for Research and Treatment of Cancer: “Pelvic lymph node dissection in prostate cancer: Pro and cons” (15-18 Ottobre, 2009, Londra, Regno Unito).
  10. Relatore della Master lecture intitolata “How to apply outcome research models to sexual medicine?” durante il 12o Meeting of the European Society for Sexual Medicine (15-18 Novembre, 2009, Lione, Francia).
  11. Relatore durante il 2o European Multidisciplinary Meeting on Urological Cancers (EMUC): “State-of-the-art-lecture: Post prostatectomy erectile dysfunction” (27-29 Novembre, 2009, Barcellona, Spagna).
  12. Relatore durante la Plenary Session del British Association of Urological Surgeons (BAUS) Annual Meeting: “Lymph node dissection in prostate cancer – Curative treatment or staging tool?” (21-24 Giugno, 2010, Manchester, Regno Unito).
  13. Relatore durante il Dibattito intitolato “Pelvic lymphadenectomy for prostate cancer: No vs limited vs extended: why extended?” during the 1st Innovation in Urology Meeting (17-19 Settembre, 2010, Milano, Italia).
  14. Relatore durante l’EORTC Genito-Urinary group Symposium: “Multidisciplinary case discussion on the management of lymph node disease in Prostate Cancer” (25-27 Marzo, 2010, Bruxelles, Belgio).
  15. Relatore durante il 4o Leading Lights in Urology Meeting: “Controversies in the management of organ confinedprostate cancer: PCA3?” (7-9 Aprile, 2011, Baveno, Italia).
  16. Relatore durante il 4o Leading Lights in Urology Meeting: “Risk assessment of bone metastases in newly diagnosedprostate cancer” (Satellite Symposium Amgen, 7-9 Aprile, 2011, Baveno, Italia).
  17. Relatore durante la Joint Session dell’European Association of Urology (EAU) e dell’Iranian Urological Association (IUA): “Sexual dysfunction after radical treatment for prostate cancer”, durante il 26o Meeting dell’European Association of Urology (18-22 Marzo, 2011, Vienna, Austria).
  18. Relatore durante il 2o Innovation in Urology Meeting “Role of surgery in high risk prostate cancer” (1-2 Ottobre, 2011, Milano, Italia).
  19. Relatore durante l’11o Annual Meeting of the Belgian Association of Urology: “Use of prostate cancer nomograms in patient tailored approach – The Belgian PCa nomogram project, final outcomes” (Sponsored lecture by Ipsen, 9-10 Dicembre, 2011, Ghent, Belgio).
  20. Relatore durante il 27o Meeting of the European Association of Urology: “Case-based update on the optimal management of bone metastases from prostate cancer”, sponsored by Amgen (24-28 Febbraio, 2012, Parigi, Francia).
  21. Relatore durante il Meeting “Urology in 2012: What’s in and What’s new”: “Unmet needs in prostate cancer diagnosis and treatment” (11 Ottobre, 2012, Pisa, Italia).
  22. Relatore durante il Global Congress on Prostate Cancer: “Lymph node dissection: when is it indicated?” and “Choline PET scan in the detection of early recurrence” (28-30 Giugno, Bruxelles, Belgio).
  23. Relatore durante il 4o European Multidisciplinary Meeting on Urological Cancers (EMUC): “What does the future hold in prostate cancer? – The future of surgery (16-18 Novembre, 2012, Barcellona, Spagna).
  24. Relatore durante il 10o Meeting of the EAU Section of Oncological Urology (ESOU), “The role of salvage lymph node dissection in prostate cancer” (18-20 Gennaio, Roma, Italia).
  25. Relatore, Souvenir Session on Prostate Cancer, 28o Meeting of European Association of Urology (EAU) (15-19 Marzo, 2013, Milan, Italy).
  26. Relatore durante la joint session dell’European Association of Urology (EAU)-Iranian Urological Association (IUA), “How to manage high risk prostate cancer” during the 28th Meeting of the European Association of Urology (15-19 Marzo, 2013, Milano, Italia).
  27. Relatore durante il 2o Global Congress on Prostate Cancer, “Non-systemic relapse after local treatment: facts and fiction” (12-14 Giugno, 2013, Marsiglia, Francia).
  28. Relatore durante il 2o Global Congress on Prostate Cancer, “Focal therapy: still utopia?” (12-14 Giugno, 2013, Marsiglia, Francia).
  29. Relatore durante l’Annual Meeting of the American Urological Association (AUA), Subspecialty Society & International Meetings – Italian Society of Urology: “Should an Extended PLND be Performed During RP” (4-8 Maggio, 2013, San Diego, USA).
  30. Relatore durante il 3o Meeting of the European Association of Urology (EAU) Section of Urological Imaging (ESUI): “Imaging guided therapy in prostate cancer will become a standard in prostate cancer management: CON” (13 Novembre, Lisbona, Portogallo).
  31. Relatore durante il 11o Meeting dell’European Association of Urology (EAU) Section of Oncological Urology (ESOU): “Local treatment of oligo-metastatic prostate cancer: Lymphadenectomy” (17-19 Gennaio, 2014, Praga, Repubblica Ceca).
  32. Relatore ed Insegnante durante il Current trends in the management of advanced prostate cancer: “Multimodal treatment in high risk prostate cancer” (20 Giugno, 2014, Tbilisi, Georgia).
  33. Relatore e Insegnate durante l’European School of Oncology (ESO) conference on Active surveillance for low risk prostate cancer: “Pitfalls and criticism of active surveillance” (21-22 Febbraio, 2014, Amsterdam, Paesi Bassi).
  34. Relatore durante il 33o Meeting dell’ European Society for Radiotherapy and Oncology (ESTRO): “Should oligometastatic prostate cancer be treated systemically? The urologist point of view” (4-8 Aprile, 2014, Vienna, Austria).
  35. Relatore durante il 29o Meeting dell’European Association of Urology “Prostate cancer: a state of the heart”, “A patient-centred approach to making treatment decisions” (Satellite Symposium Ferring, 11-15 Aprile, 2014, Stoccolma, Svezia).
  36. Relatore durante il 29o Meeting dell’European Association of Urology (EAU) “Souvenir session – prostate cancer, localized disease” (11-15 Aprile, 2014, Stoccolma, Svezia).
  37. Relatore durante la Joint Session European Association of Urology (EAU)-Korean Urological Association (KUA): “Adjuvant and salvage radiotherapy for locally advanced prostate cancer” during the 29th Meeting of the European Association of Urology (11-15 Aprile, 2014, Stoccolma, Svezia).
  38. Relatore durante la Joint Session European Association of Urology (EAU)-European Society of Nuclear Medicine (EANM): “Unmet needs in prostate cancer recurrence imaging: urological perspective”, during the 29th Meeting of the European Association of Urology (11-15 Aprile, 2014, Stoccolma, Svezia).
  39. Relatore e Insegnante, “Multimodal treatment of high risk prostate cancer”, “Role of extended lymph node dissection in high risk prostate cancer: where?, when?, how?” (6 Novembre, 2014, Bucarest, Romania).
  40. Relatore durante il 5o European Multidisciplinary Meeting on Urological Cancers (EMUC): “Salvage surgery for positive nodes in prostate cancer: novel concept in selected patients”, “Clinical Case discussion”, “Take home messages: surgery” (15-17 Novembre, 2013, Marsiglia, Francia).
  41. Relatore durante l’International Symposium on Prostate, Androgens and Men’s Sexual Health (ESSM-ISSM) “Curative treatment for prostate cancer: what is best for survival?” (21-23 Giugno, 2013, Berlino, Germania).
  42. Relatore durante il 22o Panhellenic Urological Congress: “Local treatment of oligo-metastatic prostate cancer: Lymphadenectomy”, (16-19 Ottobre, 2014, Creta).
  43. Relatore e insegnante durante il Fifth Symposium on Hormonal Treatment of Prostate Cancer (STOP 5) “The role of surgery in intermediate risk prostate cancer”, Castration resistant prostate cancer: Clinical case discussions, Oligometastatic disease/ metastases at diagnosis (workshop), Debate on the management of positive lymph nodes (17-19 Ottobre, 2014, Praga, Repubblica Ceca).
  44. Relatore durante il 6o European Multidisciplinary Meeting on Urological Cancers (EMUC): “Take home messages: surgery” (13-16 Novembre, 2014, Lisbona, Portogallo).
  45. Relatore durante l’Annual Meeting of the Urological Research Society: “Impact of adjuvant radiotherapy on survival of patients with node positive prostate cancer” (18-20 Settembre, 2014, Monaco, Germania).
  46. Relatore durante il 12o Meeting dell’European Association of Urology (EAU) Section of Oncological Urology (ESOU): “Debate: The role of choline/PSMA – PET/CT in relapsing prostate cancer following local treatment: Pro” (16-18 Gennaio, 2015, Monaco, Germania).
  47. Relatore durante il Meeting “Recent advances in the treatment of prostate cancer– focus on lymph node positive disease and metastatic castration resistant prostate cancer”, “Treatment strategies for N1/M0 desease” (20 Gennaio, 2015, Aarhus, Danimarca).
  48. Relatore durante il 3o Global Congress on Prostate Cancer, session “Surgery or radiotherapy for prostate cancer: are we comparing apples with oranges?”, “What are we talking about?” (5-7 Febbraio, 2015, Roma, Italia).
  49. Relatore durante il 3o Global Congress on Prostate Cancer, session “Targeting the AR signalling pathway: Redefining clinical practice in mCRPC?” sponsored symposium, Astellas (5-7 Febbraio, 2015, Roma, Italia).
  50. Relatore durante il 3o Global Congress on Prostate Cancer, session “Expert opinions in mCRPC treatment: what’s their recommendation?” sponsored symposium, Jannsen (5-7 Febbraio, 2015, Roma, Italia).
  51. Relatore durante l’European Section of Urological Imaging (ESUI) del 30o Meeting dell’European Association of Urology (EAU), “Critical assessmen of PET/CT in the staging of prostate cancer recurrence (20-24 Marzo, 2015, Madrid, Spagna).
  52. Discussant, Late Breaking News session, A Randomized, Double-Blind, Phase II, Efficacy and Safety Study of Enzalutamide vs. Bicalutamide in Metastatic Castrate Resistant Prostate Cancer: TERRAIN Trial durante il 30o Meeting dell’European Association of Urology (EAU) (20-24 Marzo, 2015, Madrid, Spagna).
  53. Relatore durante il 30o Meeting dell’European Association of Urology (EAU) “Souvenir session – prostate cancer, localized and disease” (20-24 Marzo, 2015, Madrid, Spagna).
  54. Relatore durante il 1o Prostate Cancer Summit, session “Treatment of metastatic disease”con la presentazione intitolata: “The role of surgery in the management of prostate cancer recurrence” (27-29 Agosto, 2015, Amburgo, Germania).
  55. Relatore durante il 15o Congress of the Russian Association of Urology session “Uro-Oncology” con la presentazione intitolata “Management of Localized Kidney Cancer” (18-20 Settembre, 2015, San Pietroburgo, Russia).
  56. Relatore durante il Meeting “Prostate Cancer: Hot Topics” con la presentazione intitolata “Treatment options for high risk prostate cancer” (23 Settembre,2015, Padova, Italia).
  57. Relatore durante il 1o Urology Robotic Oncology Paris (UROP) Meeting, Astellas sponsored symposium “mCRPC: Treatment decisions in a new therapeutic landscape” con la presentazione intitolata “Treating patients whose cancer has advanced after ADT in a new landscape” (8-9 Ottobre, 2015, Parigi, Francia)
  58. Relatore durante il 7o European Multidisciplinary Meeting on Urological Cancers (EMUC): “Take home messages: surgery” (12-15 Novembre, 2015, Barcellona, Spagna).
  59. Relatore durante l’European School of Oncology (ESO) Conference “Personalized approach to prostate cancer management” con a presentazione intitolata “What do we need in surgery” (12 Novembre, 2015, Barcellona, Spagna).
  60. Relatore durante il Meeting “Tribute to Uro-Oncology” con la presentazione intitolata “Metastases directed therapy in prostate cancer: a surgeon’s view” (20-21 Novembre, 2015, Leuven, Belgio).
  61. Relatore durante il 14o Meeting dell’Academic European Urologists (AAEU) con la presentazione intitolata: “Assessing the optimal timing for early salvage radiation therapy in patients with PSA rise after radical prostatectomy” (3-6 Dicembre, 2015, Londra, Regno Unito).
  62. Relatore durante il 2016 Genitourinary Cancer Symposium of the American Society of Clinical Oncology (GU ASCO) con la presentazione intitolata: “Incidence and Distribution of Lymph Node Metastases in Localized Prostate Cancer: Role of Imaging and Surgery” (7-9 Gennaio, 2016, San Francisco, USA).
  63. Relatore durante il “4th Techno Urology Meeting” con la presentazione intitolata “Screening for prostate cancer: Who does benefit? How to do it?” (27-29 Gennaio, 2016, Orbassano, Torino, Italia).
  64. Relatore durante la Joint Session dell’European Association of Urology (EAU) e della Korean Urological Association (KUA) con la presentazione intitolata: “Optimal Managements for biochemical recurrence: European approach” during the 31st Meeting of the European Association of Urology” (EAU- 11-15 Marzo, 2016, Monaco, Germania).
  65. Relatore durante il 17o Annual Meeting della Society of Urologic Oncology (SUO) dell’American Urological Association (AUA), “Evolving the role of Image-Guided treatment for pelvic nodal relapse after definitve local therapy” (7 MAggio, 2016, San Diego, USA).
  66. Panelist durante il 17o Annual Meeting della Society of Urologic Oncology (SUO) dell’American Urological Association (AUA), “Case-based discussion of high risk/advanced disease” (7 Maggio, 2016, San Diego, USA).
  67. Provoker durante l’Annual Meeting dell’American Urological Association (AUA), Subspecialty Society & International Meetings – Italian Society of Urology: “Prostate cancer biology, staging and grading” (9 Maggio, 2016, San Diego, USA).
  68. Relatore durante il 4o Global Congress on Prostate Cancer: “A provocative discussion on the best discovery over the the last 5 year – Surgery” and “Local disease control in clinical N+ patients” (29 Giugno – 1 Lugio, Vienna, Austria).
  69. Relatore durante l’European Association of Urology (EAU)- Chinese Urological Association (CUA) Workshop con la presentazione intitolata “Assessment of Guidelines Implementation and Education (IMAGINE)” (25-26 Agosto, 2016, Guangzhou, Cina).
  70. Relatore durante il 13o Meeting if the EAU Robotic Urology Section (ERUS) “One-stage pelvic and retroperitoenal primary or salvage lymph node dissection in prostate cancer” (14-16 Giugno, 2016, Milano, Italia).
  71. Relatore durante il 2o Urology Robotic Oncology Paris (UROP) Meeting: “Is there any further indication of active treatment for low-risk, localized prostate cancer patients? and “Exploring decision-making with new generation hormonal therapies in mCRPC patients progressing on ADT” – Astellas Symposium (13-14 Ottobre, 2016, Parigi, Francia)
  72. Relatore durante il Meeting intitolato “Lymphadeectomy in Urological surgery – Technique and Template. Myths and facts” with two lectures “How high is enough?: Limited vs Extended vs Super-extended lymph node dissection in prostate cancer” and “oncological meanings of a positive node during radical prostatectomy (a Novembre, Bergamo, Italia)
  73. Relatore durante l’“Urologie and Andrologie” annual meeting in the International Lectures session con due presentazione intitolate “Role of lymphadenectomy for prostate cancer” e “How to make successfully academic career in urology (5 Novembre, Linz, Austria)
  74. Relatore con ospite durante il Martini-Klinik Autumn Seminar “The role of metastasis-directed therapy in the era of systemic treatments in prostate cancer (18 Novembre, Amburgo, Germania)
  75. Relatore durante il 8o European Multidisciplinary Meeting on Urological Cancers (EMUC): “Take-home messages – Urologist” (24-27 Novembre, 2016, Milano, Italia).
  76. Panelist durante l’Uroforum 2016 “Debate – Management of high risk localized and locally advanced prostate cancer” (1-2 Dicembre, Barcellona, Spagna)
  77. Relatore durante il Movember Uro-Webinar “Debate on screening for prostate cancer: USPSTF recommendations against PSA testing – a good thing?” (22 Novembre, 2016)
  78. Relatore durante la Joint session dell’EAU Section of Urological Imaging (ESUI) e dell’European Association of Nuclear Medicine (EANM): “The more you look, the more you find: clinical consequences of new imaging technologies in prostate cancer” (24 Novembre, 2016, Milano, Italia).
  79. Relatore durante il 14o Meeting dell’EAU Section of Oncological Urology (ESOU), “Targeted MRI prostate biopsy: Relevant drawbacks” (20-22 Gennaio, 2017, Praga, Republica Ceca).
  80. Relatore durante il “5th Techno Urology Meeting” con la presentazione intitolata “Radical prostatectomy in oligometastatic patients: biological rationale and clinical impact” (25-27 Gennaio, 2017, Orbassano, Torino, Italia).
  81. Relatore durante il 9o Uro-Oncology Symposium “Controversies in Uro-Oncology” con una presentazione intitolata “Adjuvant and salvage radiation therapy in prostate cancer (27 Gennaio, 2017, Zurigo, Svizzera)
  82. Relatore durante l’ESUT-Expert Meeting “Management of locally confined prostate cancer” con una presentazione intitolata “Staging of prostate cancer with MRI: a real benefit or waste of money?” (4 Febbraio, 2017, Davos, Svizzera).
  83. Relatore durante l’annual meeting of the European Society of Radiology con una presentazione intitolata “Prostate biopsy strategy” (1-5 Marzo, 2017, Vienna, Austria)
  84. Relatore durante il 32o Meeting dell’European Association of Urology (EAU) nella Joint Session of the European Association of Urology (EAU) and the Confederación Americana de Urología (CAU) con una presentazione intitolata “High risk localised prostate cancer, radical prostatectomy versus radiotherapy” (24-28 Marzo, 2017, Londra, Regno Unito).
  85. Relatore durante il 32o Meeting dell’ European Association of Urology (EAU) nella Joint Session of the European Association of Urology (EAU) and the japanese Uroogical Association (JUA) con una presentazione intitolata “Extending the use of androgen receptor targeted drugs in men with nmCRPC: No” (24-28 Marzo, 2017, Londra, Regno Unito).
  86. Relatore durante il 32nd Meeting dell’European Association of Urology (EAU) nel Meeting of the Young Academic Urologists (YAU) con una presentazione intitolata “Establishing a professional carreer at a European level: Motivational talk by Crystal Matula Award Winner” (24-28 Marzo, 2017, Londra, Regno Unito).
  87. Relatore durante il 32o Meeting dell’European Association of Urology (EAU) nel Meeting of the EAU Section of Urological Imaging (ESUI) in cooperation with the EAU Section of Urological Research (ESUR) and the European Society of Nuclear Medicine (EANM) con una presentazione intitolata: “Controversies – Focal therapy and the concept of the index lesion: Nonsense” (24-28 Marzo, 2017, Londra, Regno Unito).
  88. Relatore durante il Meetin annuale dell’American Society of Clinical Oncology (ASCO) in the Education session: Disparities in Screening and Treatment of Prostate Cancer for the Older Patient con una presentazione intitolata: “Does Prostate Cancer Presentation and Biologic Characteristics Differ in Older Patients?” (2-6 Giugno, 2017, Chicago, USA)
  89. Relatore durante il 1° EAU Update on Prostate Cancer Meeting con una presentazione intitolata: “Salvage local treatment for recurrent disease” (15-16 Settembre, 2017, Vienna, Austria)
  90. Relatore durante il 14o Meeting if the EAU Robotic Urology Section (ERUS) con una lettura intitolata “How to find lymph nodes suspicious on preoperative PSMA PET Scan: How to do it” (25-27 Settembre, 2017, Bruges, Belgio).
  91. Relatore durante il 2018 Genitourinary Cancer Symposium of the American Society of Clinical Oncology (GU ASCO) con la presentazione intitolata: “Adjuvant radiotherapy and Chemotherapy in node positive prostate cancer” (8-10 Febbraio, 2018, San Francisco, USA)
  92. Relatore durante il 2° EAU Update on Prostate Cancer Meeting con la relazione intitolata “Salvage treatment for recurrent disease” (14-15 Settembre, Milano, Italia)
  93. Relatore durante il 33° Meeting of the European Association of Urology (EAU) in the 5th ESO Prostate Cancer Observatory con la presentazione intitolata: “The urologist’s perspective on surgery” (16-20 Marzo, 2018, Copenhagen, Danimarca)
  94. Relatore durante il 33° Meeting of the European Association of Urology (EAU) during the Meeting of the Young Acamedic Urologists (YAU) con la presentazione intitolata: “PROTECT trial and sexual outcomes: Lights and shadows” (16-20 Marzo, 2018, Copenhagen, Danimarca)
  95. Moderatore durante 33° Meeting of the European Association of Urology (EAU) – Plenary session 3 “PET/CT detected oligometastatic prostate cancer” (16-20 Marzo, 2018, Copenhagen, Danimarca)
  96. Relatore durante il 55° Urology Course of Fundacio Puigvert con le presentazioni intitolate “Active suveillance vs focal treatment. Does the vascular-targeted photodynamic therapy trial make a difference?” e “Lymphadenectomy in prostate cancer: when, how, for what?” (17-19 Settembre, 2018, Barcellona, Spagna)
  97. Speaker durante la discussione del caso multidisciplinare “Controversies and contradictions in staging of prostate cancer” durante il 10° European Multidisciplinary Meeting on Urological Cancers (EMUC) (8-11 Novembre, 2018, Amsterdam, Paesi Bassi)
  98. Relatore durante il 10° European Multidisciplinary Meeting on Urological Cancers con la presentazione intitolata: “Everything in prostate cancer pathology you were afraid to ask” (8-11 Novembre, 2018, Amsterdam, Paesi Bassi)
  99. Relatore durante il 16° Meeting dell’EAU Section of Urology Oncology (ESOU) con la lettura intitolata: “Reliability of PET/CT in the primary staging of prostate cancer” (18-20 Gennaio, 2019, Praga, Repubblica Ceca)
  100. Relatore durante il 2019 Genitourinary Cancer Symposium of the American Society of Clinical Oncology (GU ASCO) con la presentazione intitolata: Intensification Versus Deintensification in High-Risk Prostate Cancer: Surgery” (14-16 Febbraio, 2019, San Francisco, USA)
  101. Relatore durante il 34° Meeting dell’ European Association of Urology (EAU) durante la Joint Sesssion dell’EAU e dell’Urological Society of Australia and New Zeland (USANZ) con la presentazione intitolata: “Prostate biopsy: is multiparametric MRI the decision maker?” (15-19 Marzo, 2019, Barcellona, Spagna)
  102. Discussant dello studio: “The role of (fast) bi-parametric MRI versus multi- parametric MRI and TRUS-biopsy for detecting clinically significant prostate cancer in biopsy naïve men with elevated PSA in Plenary Session 3” durante il 34° Meeting dell’European Association of Urology (EAU) (15-19 Marzo, 2019, Barcellona, Spagna)
  103. Relatore durante il Meeting dell’European Association of Urology (EAU) nella Souvenir session (Plenary session 7) con la presentazione intitolata: “Prostate cancer: localized and advanced disease” (15-19 Marzo, 2019, Barcellona, Spagna)
  104. Relatore durante il 6° Multidisciplinary Meeting on Prostate Cancer con le resentazioni intitolate “Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018” e “A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imagingtargeted and Systematic Biopsies” (21-22 Febbraio, 2019, Bilbao, Spagna)
  105. Relatore durante il corso Fundacio Puigvert sul Advanced Prostate Cancer Treatment con le presentazioni intitolate “Therapeutic Options after pelvic and extra- pelvic nodal recurrence” e “How to perform lymphadenectomy in locally advance case? Technique and management of complications” (28 Marzo, 2019, Barcellona, Spagna)
  1. Poster session 42: Sexual dysfunction and the treatment of pelvic malignancy durante il 22o Annual Meeting dell’European Association of Urology. (21-24 Marzo, 2007, Berlino, Germania).
  2. Poster Session 56: Radical prostatectomy: Age, comorbidities and complications durante il 23o Meeting dell’European Association of Urology (26-29 Marzo, 2008, Milano, Italia).
  3. Poster Session 55 Prostate cancer: Diagnosis and staging durante il 24o Meeting dell’European Association of Urology (17-21 Marzo, 2009, Stoccolma, Svezia).
  4. Podium session P-6: Erectile Dysfunction following RadicalProstatectomy durante il 9o Meeting dell’European Society for Sexual Medicine (ESSM) (3-6 Dicembre, 2006, Vienna, Austria).
  5. Podium session P-04: Erectile dysfunction durante il 10o Meeting dell’European Society for Sexual Medicine (ESSM) (25-28 Novembre, 2007, Lisbona, Portogallo).
  6. Highlight Session durante l’Annual 11o Annual Meeting dell’European Society for Sexual Medicine (ESSM) (7-11 Dicembre, 2008, Bruxelle, Begio).
  7. Poster Session: Andrology durante l’82o Annual Meeting of della Società Italiana di Urologia (4-7 Ottobre, 2009, Rimini, Italia).
  8. Session Papers A: Prostate cancer treatment durante il British Association of Urological Surgeons (BAUS) Annual Meeting (21-24 Giugno, 2010, Manchester, Regno Unito).
  9. Session entitled: “Re-defintion of the oncological risk” durante l’83o Annual Meeting della Società Italiana di Urologia (17-20 Ottobre, 2010, Milano, Italia).
  10. Highlight session durante l’83o Annual Meeting della Società Italiana di Urologia (17-20 Ottobre, 2010, Milano, Italio).
  11. Highlight session durante l’84o Annual Meeting della Società Italiana di Urologia (23-26 Ottobre, 2011, Roma, Italia).
  12. Poster session 11: “How to improve prostate cancer detection” durante il 26o Meeting dell’European Association of Urology (18-22 Marzo, 2011, Vienna, Austria).
  13. Session “Lymphadenectomy in uro–oncology”, durante l’85o Annual meeting della Società Italiana di Urologia (21-24 Ottobre, 2012, Venezia, Italia).
  14. Highlight session durante l’85o Annual Meeting della Società Italiana di Urologia (21-24 Ottobre, 2012, Venezia, Italia).
  15. Poster session (P216-P227): “Prostate Cancer: Surgical Therapy” durante l’85o Annual Meeting della Società Italiana di Urologia (21-24 Ottobre, 2012, Venezia, Italia).
  16. Poster session (P248-P263): “Andrology” durante l’85o Annual Meeting della Società Italiana di Urologia (21-24 Ottobre, 2012, Venezia, Italia).
  17. Session “Modern imaging in prostate cancer: the light at the end of the tunnel?” durante il 2o Global Congress on Prostate Cancer (12-14 Giugno, 2013, Marsiglia, Francia).
  18. Session “AFU Corner”, durante l’86o Annual Meeting della Società Italiana di Urologia (5-8 Ottobre, 2013, Milano, Italia).
  19. Moderatore durante la live surgery session al “2nd Techno Urology Congress: improving minimally invasive surgery” (30-31 Gennaio, 2014, Orbassano, Torino, Italia).
  20. Workshop Radiotherapy and/or salvage hormonoterapy after failure of surgery in High risk Prostate Cancer durante il 23o Meeting della Società Italiana di Uro-Oncologia (SIUrO) (8-10 Giugno, 2013, Firenze, Italia).
  21. Session “Node positive/oligometastatic prostate cancer” durante il 5o Meeting: “Embracing Excellence in Prostate, Bladder and Kidney Cancer” (EMUC): “Take home messages: surgery” (15-17 Novembre, 2013, Marsiglia, Francia).
  22. Sessions “Quality assessment in uro-oncology” durante il 6à Meeting: “Embracing Excellence in Prostate, Bladder and Kidney Cancer” (EMUC) and “Take home messages: surgery” (13-16 Novembre, 2014, Lisbona, Portogallo).
  23. Session “Screening and diagnosis of prostate cancer” durante il “Oncoforum Summary Meeting” (28-29 Novembre, 2014, Parigi, Francia).
  24. Session “Localized prostate cancer- part 2” durante il “Oncoforum Summary Meeting” (29-30 Novembre, 2014, Praga, Repubblica Ceca).
  25. Session “Optimal management of relapsing/oligometastatic disease” durante il 3o Global Congress on Prostate Cancer (5-7 Febbraio, 2015, Roma, Italia).
  26. Chair della Thematic Session: “Imaging in Prostate Cancer” durante il 30o Meeting dell’European Association of Urology (EAU) (20-24 Marzo, 2015, Madrid, Spagna).
  27. Chairman durante il 3o Global Congress on Prostate Cancer, session “Targeting the AR signalling pathway: Redefining clinical practice in mCRPC?” sponsored symposium, Astellas (5-7 Febbraio, 2015, Roma, Italia).
  28. Session “Urothelial Carcinoma and Live Surgery” durante il 1o Urology Robotic Oncology Paris (UROP) Meeting (8-9 Ottobre, 2015, Parigi, Francia)
  29. Session “What’s new in prostate cancer” durante l’88o Annual Meeting della Società Italiana di Urologia (10-13 Ottobre, 2015, Riccione, Italia).
  30. Chairman durante l’88o Annual Meeting della Società Italiana di Urologia, sessione “Role of enzalutamide in the treatment of patient with mCRPC prior to chemotherapy” sponsored symposium, Astellas (10-13 Ottobre, 2015, Riccione, Italia).
  31. Co-Chairman durante il 4o Meeting dell’EAU Section of Urological Imaging (ESUI) nella sessione “Molecular imaging in Urology: Joint sessions of the EAU Section of Urological Imaging (ESUI) dell’European Association of Nuclear Medicine (EANM)” (12 Novembre, 2015, Barcellona, Spagna).
  32. Co-chairman durante il 7o European Multidisciplinary Meeting on Urological Cancers (EMUC): “Prostate cancer in the young patient” (12-15 Novembre, 2015, Barcellona, Spagna).
  33. Co-chairman durante la 3a Conference on Active Surveillance for Low Risk Prostate Cancer, European School of Oncology (ESO) nella sessione “Current selection of men for active surveillance” (12-13 Febbraio, Milano, Italia).
  34. Co-Chairman durante la Joint Session dell’European Association of Urology (EAU) e la Korean Urological Association (KUA) nella sessione “Prostate cancer: Biochemical recurrence after radical prostatectomy” durante il 31o Meeting dell’European Association of Urology (EAU) (11-15 Marzo, 2016, Monaco, Germania)
  35. Sessione di “Live Surgery” durante il 2o Urology Robotic Oncology Paris (UROP) Meeting (13-14 Ottobre, 2016, Parigi, Francia)
  36. Chairman della sessione: “Lecture: The role of micro-environment in GU cancers” durante l’8o European Multidisciplinary Meeting on Urological Cancers (EMUC) (24-27 Novembre, 2016, Milano, Italia).
  37. Co-chairman durante la sessione: “Announcement of the 3 best unmoderated posters” durante l’8o European Multidisciplinary Meeting on Urological Cancers (EMUC) (24-27 Novembre, 2016, Milano, Italia).
  38. Co-chairman durante la Joint session dell’EAU Section of Urological Imaging (ESUI) e dell’European Association of Nuclear Medicine (EANM) nella sessione intitolata: “Molecular imaging in Urology” (24 Novembre, 2016, Milano, Italia).
  39. Co-chairman dell’EMUC symposium on Genito-Urinary Pathology and Molecular Diagnostics (ESUP) intitolata“Frome the latest novelties to guidelines and protcols” (24 Novembre, 2016, Milano, Italia).
  40. Co-chairman della sessione: “Treatment of metastatic prostate cancer” durante l’Annula Meeting dell’Associazione Italiana di Urologia (15-18 Ottobre, 2016, Venezia, Italia)
  41. Co-chairman della plenary session 5 durante il 32o Meeting dell’European Association of Urology (EAU) (24-28 Marzo, 2017, Londra, Regno Unito)
  42. Co-chairman della Podium Session: “Prostate Cancer: Localized: Surgical Therapy I” durante l’Annula Meeting dell’American Urological Association (AUA) (12-16 Maggio, Boston, USA)
  43. Co-chairman della session Prostate cancer- Tailoring the therapy durante il “5th Techno Urology Meeting” (25-27 Gennaio, 2017, Orbassano, Torino, Italia).
  44. Co-chairman della sessione Diagnosis of prostate cancer – solutions for fusion biopsy durante il ESUT-Expert Meeting “Management of locally confined prostate cancer” (4 Febbraio, 2017, Davos, Svizzera).
  45. Co-chairman della sessione “Future perspectives in prostate cancer management” durante il 1° EAU Update on Prostate Cancer Meeting (15-16 Settembre, Vienna, Austria)
  46. Co-chairman della Thematic session 06 “Semi-live session: Oncological surgery under scrutinity” durante il 33° Meeting dell’European Association of Urology (EAU) (16-20 Marzo, 2018, Copenhagen, Danimarca).
  47. Co- Chairman della Plenary session 5 durante il 34° Meeting dell’European Association of Urology (EAU) (15-19 Marzo, 2019, Barcellona, Spagna).

Contatti – Studio Privato

Discipline Urologiche Andrologiche Milanesi (DUAM)

Via Fontana, 2, 20122 Milano

tel: +390276316689

Fax:+390276010185

Contatti – Ospedale San Raffaele

Unità Operativa di Urologia Ospedale San Raffaele

Via Olgettina 60, 20132 Milano

Tel. +390226432643

Fax. +390226437298

Gentile Paziente

In considerazione della situazione di emergenza sanitaria legata al COVID 19 – Corona Virus, e’ ora altamente raccomandabile essere visitati per via telematica rimanendo al proprio domicilio.

Questi sono i passaggi necessari:

1. Telefonare oppure inviare email allo studio DUAM (tel 02 7631 6689 – indirizzo email: prenotazioni@duam.it) per richiedere appuntamento per la visita specialistica

2. La segreteria DUAM fornira’ un appuntamento preciso (giorno e ora) per la visita. Verranno fornite le informazioni necessarie a fare pervenire per via telematica la documentazione clinica necessaria alla valutazione del caso (es: esami di laboratorio, radiografie, ecografie, TC, RM, esami specialistici di qualsiasi tipo, fotografie).

3. La visita verra’ eseguita per via telematica ed Suo quadro clinico verra’ valutato in modo da porterLa aiutare al meglio

In attesa di poterLa sentire di persona porgo i saluti più cordiali

Prof. Alberto Briganti

Prenota ora online